A5076430463- Bone health and treatments
- Management of metastatic bone disease
- Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Screening and Detection
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Medical Imaging and Pathology Studies
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Pain Management and Opioid Use
- Pharmaceutical Economics and Policy
- Multiple and Secondary Primary Cancers
- Molecular Biology Techniques and Applications
- Neutropenia and Cancer Infections
- Pharmaceutical Practices and Patient Outcomes
- Nausea and vomiting management
- Advances in Oncology and Radiotherapy
Grail (United States)
2020-2025
Menlo School
2020-2025
Illumina (United States)
2022-2024
Texas A&M Health Science Center
2022-2023
BioStrategies (United States)
2023
Texas A&M University
2023
University of California Davis Medical Center
2022
Bristol-Myers Squibb (United States)
2021
University of Washington
2010-2019
Jazz Pharmaceuticals (United States)
2017-2019
Abstract BACKGROUND: In this study, the authors evaluated effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. METHODS: The prevention pain, reduction interference daily life activities, proportion requiring strong opioid analgesics were assessed a randomized, double‐blind, double‐dummy phase 3 study comparing ZA for preventing skeletal‐related events 2046 who had Patients completed Brief Pain Inventory‐Short Form at baseline...
Abstract Purpose: Denosumab was shown to be superior zoledronic acid in preventing skeletal related events (SRE) patients with breast cancer and bone metastases a randomized, double-blind phase III study. We evaluated further results from this study complications health-related quality of life (HRQoL). Experimental Design: Patients were randomized 1:1 receive subcutaneous denosumab 120 mg (n = 1,026) intravenous placebo, or 4 1,020) placebo every weeks. Analyses reported here include the...
Chimeric antigen receptor (CAR) T-cell therapies are currently administered at a limited number of cancer centers and primarily delivered in an inpatient setting. However, variations total costs associated with these remain unknown.
To examine the extent of evaluation required to achieve diagnostic resolution and test performance characteristics a targeted methylation cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test, ~6200 participants ≥50 years with (cohort A) or without B) ≥1 3 additional specific cancer risk factors will be enrolled in PATHFINDER (NCT04241796), prospective, longitudinal, interventional, multi-center study. Plasma cfDNA from blood samples analyzed detect abnormally methylated...
Multi-cancer early detection (MCED) next-generation-sequencing blood tests represent a potential paradigm shift in screening.
Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis treatment cancer at earlier stages may reduce this burden. To better understand potential impacts diagnosis, healthcare costs among patients with were assessed by type stage diagnosis.A retrospective analysis was conducted using Optum's de-identified Integrated Claims-Clinical data set Enriched Oncology, which includes from Medicare Advantage commercially insured...
POCKETT R.D., CASTELLANO D., MCEWAN P., OGLESBY A., BARBER B.L. & CHUNG K. (2010) European Journal of Cancer Care19, 755–760The hospital burden disease associated with bone metastases and skeletal-related events in patients breast cancer, lung or prostate cancer Spain Metastatic (MBD) is the most common cause pain serious (SREs) reducing quality life. Management MBD involves a multimodal approach aimed at delaying first SRE subsequent SREs. The objective study was to characterise SREs...
Giant cell tumor of bone (GCTB) is an aggressive primary osteolytic tumor. GCTB often involves the epiphysis, usually causing substantial pain and functional disability. Denosumab, a fully human monoclonal antibody against receptor activator nuclear factor κΒ ligand (RANKL), effective treatment option for patients with advanced GCTB. This analysis data from ongoing, open-label study describes denosumab's effects on analgesic use in GCTB.Patients unresectable disease (e.g. sacral or spinal...
The Brief Pain Inventory-Short Form (BPI-SF) is widely used for assessing pain in clinical and research studies. worst rating often the primary outcome of interest; yet, no published data are available on its minimally important difference (MID). Breast cancer patients with bone metastases enrolled a randomized, double-blind, phase III study comparing denosumab zoledronic acid preventing skeletal related events completed BPI-SF, FACT-B, EQ-5 Datbaseline, week 5, monthly through end study....
Estimate the annual cost of care in 5 years following a cancer diagnosis for 17 invasive types, by stage at diagnosis.We used 2012-2016 data from Surveillance, Epidemiology, and End Results (SEER) registry-Medicare claims database to examine among Medicare beneficiaries with confirmed based on International Classification Diseases Oncology, Third Edition histology codes reported SEER. Beneficiaries contributed calculations (Years 1-5) using their observed time after diagnosis. were...
Diminished immune defense plays an important role in cancer development. Cancer risk immunocompromised patients may differ. Identifying individuals with elevated can inform strategies for routine screening. This study aimed to understand and compare incidence three patient groups: recipients of solid organ transplant (SOT) or hematopoietic stem cell (HSCT); diagnosis primary secondary immunodeficiency disorder (PID/SID); tumor necrosis factor inhibitor (TNF-i) therapy.This retrospective...
With increasing healthcare resource constraints, it has become important to understand the incremental cost-effectiveness of new medicines. Subcutaneous denosumab is superior intravenous zoledronic acid (ZA) for prevention skeletal-related events (SREs) in patients with advanced solid tumors and bone metastases. This study sought determine lifetime vs ZA this setting, from a US managed-care perspective.
Acute myeloid leukemia (AML) is associated with high disease burden. This analysis estimated HRU and costs among newly diagnosed AML patients in a US commercially insured population.This was retrospective observational study using the IMS Health PharMetrics Plus Hospital Charge Detail Master databases. Patients included adults who were between January 2007 June 2016 ("study period"). <12 months of continuous enrollment prior to index date excluded, as those whose first diagnosis...
Emerging blood-based multi-cancer early detection (MCED) tests can detect a variety of cancer types across stages with range sensitivity, specificity, and ability to predict the origin signal. However, little is known about general US population's preferences for MCED tests.To quantify among adults aged 50-80 years using discrete choice experiment (DCE).To attributes tests, an online DCE was conducted five (true positives, false negatives, likelihood type unknown, number detected),...
Many patients with advanced cancer frequently use analgesic medications for their pain. Systematically assessing and quantifying changes in remains challenging the clinical trials setting. Currently, there is no sensitive scale categorizing intensity of to understand reasons patient-reported We assessed whether Analgesic Quantification Algorithm (AQA) more than World Health Organization Treatment Ladder (WHO-AL) medication among cancer. An expanded equianalgesic potency conversion table was...